Table 2.
Bacterial Plasmids and Bacmids Used in this Study
| Plasmid | Description |
|---|---|
| pGEM®‐T Easy | ColE1‐based cloning vector; 3,015 bp, Apr (Promega #A1360) |
| pUC57 | ColE1‐based cloning vector; 2,710 bp, Apr (GenScript #SD1176) |
| pEYFP‐C1 | pBR322 origin vector containing Aequorea victoria GFP; 4,731 bp, Knr (Clontech, discontinued) |
| pFastbac™ Dual | pUC‐based vector containing MCSs after the polH and p10 promoters; 5,238 bp, Apr Gnr (Thermo Fisher Scientific #10712–024) |
| pAcVE.01 | Derivative of pUC57; described in materials and methods section |
| pAcVE.02 | Derivative of pAcVE.01; described in materials and methods and Figure 4 |
| pAcVE.03 | Derivative of pAcVE.01; described in materials and methods and Figure 4 |
| pAc.01 | Derivative of pAcVE.01 where the 516 bp P‐vank‐1 gene has been deleted |
| pAc.02 | Derivative of pAcVE.02 where the 516 bp P‐vank‐1 gene has been deleted |
| pAc.03 | Derivative of pAcVE.03 where the 516 bp P‐vank‐1 gene has been deleted |
| epo‐pUC57 | 607 bp codon optimized epo gene from human cells cloned into EcoRI site of pUC57 |
| pKH25 | 510 bp NcoI/XhoI DNA from epo‐pUC57 containing epo (PCR primers 363/364) cloned into pGEM®‐T Easy |
| epo‐pAc.03 | 504 bp NcoI/XhoI fragment from pKH25 containing epo with no stop codon cloned into pAc.03 |
| epo‐pAcVE.03 | 504 bp NcoI/XhoI fragment from pKH25 containing epo with no stop codon cloned into pAcVE.03 |
| seap‐pUC57 | 509 bp codon optimized seap gene from human cells cloned into EcoRI site of pUC57 |
| seap‐pAc.02 | Derivative of seap‐pAcVE.02 where the 516 bp P‐vank‐1 gene has been deleted |
| seap‐pAcVE.02 | 1,504 bp NotI/SbfI from seap‐pUC57 containing seap with stop codon cloned into pAcVE.02 |
| pVL‐YFP | BamHI/SmaI fragment from pEYFP‐C1 containing yfp cloned into pVL1392 |
Abbreviations: (Apr) ampicillin resistance, (Knr) kanamycin resistance, (Gnr) gentamicin resistance, (polH) polyhedrin, (seap) secreted embryonic alkaline phosphatase, (epo) erythropoietin.